Sutro Biopharma Inc. (STRO)
Sutro Biopharma Statistics
Share Statistics
Sutro Biopharma has 82.46M shares outstanding. The number of shares has increased by 32.06% in one year.
| Shares Outstanding | 82.46M |
| Shares Change (YoY) | 32.06% |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | 76.2% |
| Shares Floating | 74.61M |
| Failed to Deliver (FTD) Shares | 200 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 3.85M, so 4.67% of the outstanding shares have been sold short.
| Short Interest | 3.85M |
| Short % of Shares Out | 4.67% |
| Short % of Float | 5.05% |
| Short Ratio (days to cover) | 3.69 |
Valuation Ratios
The PE ratio is -2.42 and the forward PE ratio is -0.55. Sutro Biopharma's PEG ratio is 0.1.
| PE Ratio | -2.42 |
| Forward PE | -0.55 |
| PS Ratio | 1.68 |
| Forward PS | 0.6 |
| PB Ratio | 1.72 |
| P/FCF Ratio | -2.23 |
| PEG Ratio | 0.1 |
Enterprise Valuation
Sutro Biopharma Inc. has an Enterprise Value (EV) of 371.58M.
| EV / Earnings | -3.48 |
| EV / Sales | 2.42 |
| EV / EBITDA | -5.47 |
| EV / EBIT | -4.16 |
| EV / FCF | -3.21 |
Financial Position
The company has a current ratio of 4.5, with a Debt / Equity ratio of 0.22.
| Current Ratio | 4.5 |
| Quick Ratio | 4.5 |
| Debt / Equity | 0.22 |
| Total Debt / Capitalization | 18.35 |
| Cash Flow / Debt | -3.32 |
| Interest Coverage | -3.76 |
Financial Efficiency
Return on equity (ROE) is -0.71% and return on capital (ROIC) is -58.71%.
| Return on Equity (ROE) | -0.71% |
| Return on Assets (ROA) | -0.23% |
| Return on Capital (ROIC) | -58.71% |
| Revenue Per Employee | $502,388.89 |
| Profits Per Employee | $-348,996.73 |
| Employee Count | 306 |
| Asset Turnover | 0.33 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 18.19M |
| Effective Tax Rate | -0.21 |
Stock Price Statistics
The stock price has increased by -68.08% in the last 52 weeks. The beta is 1.15, so Sutro Biopharma's price volatility has been higher than the market average.
| Beta | 1.15 |
| 52-Week Price Change | -68.08% |
| 50-Day Moving Average | 1.87 |
| 200-Day Moving Average | 3.22 |
| Relative Strength Index (RSI) | 36.76 |
| Average Volume (20 Days) | 1.07M |
Income Statement
In the last 12 months, Sutro Biopharma had revenue of 153.73M and earned -106.79M in profits. Earnings per share was -1.78.
| Revenue | 153.73M |
| Gross Profit | 146.91M |
| Operating Income | -89.28M |
| Net Income | -106.79M |
| EBITDA | -67.92M |
| EBIT | -89.28M |
| Earnings Per Share (EPS) | -1.78 |
Balance Sheet
The company has 69.27M in cash and 33.63M in debt, giving a net cash position of 35.63M.
| Cash & Cash Equivalents | 69.27M |
| Total Debt | 33.63M |
| Net Cash | 35.63M |
| Retained Earnings | -559.41M |
| Total Assets | 451.83M |
| Working Capital | 274.49M |
Cash Flow
In the last 12 months, operating cash flow was -111.62M and capital expenditures -4.32M, giving a free cash flow of -115.93M.
| Operating Cash Flow | -111.62M |
| Capital Expenditures | -4.32M |
| Free Cash Flow | -115.93M |
| FCF Per Share | -1.93 |
Margins
Gross margin is 95.57%, with operating and profit margins of -58.07% and -69.47%.
| Gross Margin | 95.57% |
| Operating Margin | -58.07% |
| Pretax Margin | -57.63% |
| Profit Margin | -69.47% |
| EBITDA Margin | -44.18% |
| EBIT Margin | -58.07% |
| FCF Margin | -75.41% |
Dividends & Yields
STRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -112.66% |
| FCF Yield | -88.98% |
Analyst Forecast
The average price target for STRO is $12, which is 659.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 659.5% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -1.54 |
| Piotroski F-Score | 3 |